Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Garetosmab · Pasatru, REGN-2477

Monoclonal antibody · Antagonist of activin A (INHBA) · developed by Regeneron Pharmaceuticals

Approved FDA, Aug 2026
REGN Developer

What is Garetosmab?

Garetosmab is a human IgG4 monoclonal antibody that binds activin A and inhibits its signaling, blocking activation of the FOP-mutant ACVR1 receptor. It is studied in fibrodysplasia ossificans progressiva, a condition of heterotopic bone formation.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Pasatru, REGN-2477, PASATRU
Drug type
Monoclonal antibody
Targets
activin A (INHBA), ACVR1 (ALK2) (ACVR1) (binding partner it blocks)
Mechanism
Antagonist of activin A (INHBA)
Pathways
BMP/activin signaling through mutant ACVR1, heterotopic ossification
Therapy area
Musculoskeletal
Developer
Regeneron Pharmaceuticals, Inc (REGN)
FDA status
Approved as Pasatru (August 19, 2026), BLA761508 · FDA label
UNII
KR9ZSKO5QE

✅ FDA-approved uses

From the indications section of the FDA label (version of Aug 14, 2026). Read the full label for the exact wording, limitations and safety information.

Conditions studied

Fibrodysplasia Ossificans ProgressivaFOP

More from Regeneron Pharmaceuticals

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the REGN page.

Follow REGN, the company behind Garetosmab

See REGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

REGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.